Evidence map›Paper›PMID 40078978›Full record

ReviewBiosafety and health2024

Towards the first synthetic eukaryotic cell.

Wangyue Xu, Yue Teng, Sijie Zhou

Abstract readReview
In one paragraph

Review in Biosafety and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wangyue XuFrontiers Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
Yue TengState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.
Sijie ZhouFrontiers Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the rapid advance in synthetic biology and the expanding field of synthetic genomics, the realization of a redesigned yeast genome has become an achievable milestone. Multiple eukaryotic chromosomes, meticulously designed and synthesized, are now being systematically integrated to create an entirely synthetic eukaryotic cell. This comprehensive review examines the fundamental design principles and construction strategies, highlighting critical technological breakthroughs in pursuing the first synthetic eukaryotic cell. Additionally, it underscores the critical contributions of the Sc2.0 project, which has provided essential tools and engineered cellular platforms that have significantly accelerated research and industrial progress. The ethical and legal implications arising from synthetic eukaryotic life are also explored, offering insights into future research directions for synthetic eukaryotic genomes. The remarkable advances in deoxyribonucleic acid synthesis hold immense potential, promising to unlock new opportunities across medicine, industry, agriculture, and research.

Indexed as

EukaryotesSynthetic biologySynthetic genomics

Identifiers

PMID40078978
PMCPMC11895034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.